PT  - JOURNAL ARTICLE
AU  - Fernández-Gajardo, Rodrigo
AU  - Urra, Hery
AU  - Saéz, Mauricio
AU  - Pihán, Philippe
AU  - Fonseca, Beatriz
AU  - Sanchez-Doñas, Carolina
AU  - Ali, Maruf M. U.
AU  - Rouse, Sarah L.
AU  - Cavada, Gabriel
AU  - Tissera, Claudia
AU  - Melo, Rómulo
AU  - Rojas, David
AU  - Matamala, José M.
AU  - Hetz, Claudio
TI  - Characterization of the mutational landscape of high-grade gliomas in a Latin American cohort
AID  - 10.1101/2023.12.05.23299374
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.05.23299374
4099  - http://medrxiv.org/content/early/2023/12/05/2023.12.05.23299374.short
4100  - http://medrxiv.org/content/early/2023/12/05/2023.12.05.23299374.full
AB  - Background Glioblastoma, an aggressive form of high-grade glioma, exhibits variations in the incidence and mortality patterns between populations of different ancestry. However, Hispanic and Latino populations remain largely underrepresented in studies of molecular characterization. Here we characterized the mutagenic landscape of high-grade gliomas within a Chilean population focusing on well characterized genetic variants associated with glioblastoma classification, progression, and prognosis.Methods We conducted a targeted genomic analysis using next-generation sequencing techniques in 70 Chilean patients with high-grade gliomas from a national single-center referral institution. We focused on the most relevant molecular markers such as isocitrate dehydrogenase 1/2 (IDH) mutations, telomerase reverse transcriptase promoter (TERTp) mutations, histone 3 (H3) gene family mutations, TP53 and PTEN mutations, epidermal growth factor receptor (EGFR) gene amplification, and cyclin-dependent kinase inhibitor 2A (CDKN2A) deletions. Survival analyses were performed to assess the clinical relevance of these markers and their impact on patient prognosis. Additionally, due to our interest in the role of proteostasis and glioblastoma, we investigated possible ERN1 variants in our Chilean cohort.Results Our findings mostly align with other international cohorts of non-Latin-American origin, confirming the importance of established molecular markers in glioblastoma. Notably, we identified novel TP53 and PTEN mutations with a predicted damaging effect, expanding the genetic spectrum of alterations in these brain tumors. Furthermore, a lower-than-expected mutation rate in the NF1 gene was observed, emphasizing a distinctive genetic profile of glioblastoma in this Latin American population. Prognostic assessments based on TERT promoter and IDH mutations mirrored previous studies on non-Latino American and European populations. Of note, we identified the germline ERN1 variant rs139229826 in 11% of our patient cohort, a variant previously unreported in glioblastoma patients.Conclusion This study underscores the importance of conducting glioblastoma research in underrepresented populations, providing insights into the molecular characteristics of high-grade gliomas within a Latin American context. Our findings contribute to the growing body of evidence suggesting molecular diversity across diverse glioblastoma populations, offering a foundation for future international comparative studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily funded by ANID/FONDECYT 1220573 (CH), FONDAP program 15150012 (CH), and funds from the Metropolitan East Health Service and the Department of Neurological Sciences of the University of Chile. We also thank support by the U.S. Air Force Office of Scientific Research FA9550-21-1-0096, Department of Defense grant W81XWH2110960, Millennium Institute P09-015-F (CH), ANID/FONDEF ID1ID22I10120, ANID/FONDECYT 11180825 (HH), postdoctoral ANID/FONDECYT 3210294 (PP), doctoral ANID/FONDECYT fellowship (RF), ANID/NAM22I0057 and Swiss Consolidation Grant -The Leading House for the Latin American Region (CH). This study is dedicated to Virgina Flores Kehr (CH family member) who died of glioblastoma during the course of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Metropolitan East Health Service and University of Chile.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors